Roche will have to compete with $TGTX's ublituximab in #MultipleSclerosis which has a 90 minute infusion time and might be more efficacious/ lower price. Data read out in August. A buyout of $HALO for subcutaneous supremacy @Roche &amp; carve out existing deals with $JNJ $BMY $ARGX? https://t.co/k3cLxLNcLd